LY3502970

oral non-peptide GLP-1R GPCR partial agonist

in Ph. I for Type 2 diabetes, HV study complete

from cell-based screen and opt.

PNAS, Nov. 11, 2020

Chugai, Shizuoka, JP / Eli Lilly, Indianapolis, IN

Chugai/Lilly clinical oral non-peptide GLP-1R GPCR partial agonist


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.